In recent years, the incidence of breast cancer has been increasing year by year, and now it has become the number one malignant tumor among Chinese women, which seriously threatens the life and health of the majority of women. Relevant data show that about 270,000 women are newly diagnosed with breast cancer and 70,000 die from breast cancer in China every year, and 5.6 household women are diagnosed with cancer every day in Guangzhou alone. Precision treatment makes breast cancer one of the tumors with the highest cure rate at present Breast cancer is divided into several molecular subtypes, including Luminal A, Luminal B, HER2-positive and triple-negative breast cancer, etc. Why should breast cancer be molecularly typed? The characteristics of different subtypes of breast cancer vary, and the prognosis and response to treatment will be different for different groups of people who develop the disease. Although the incidence of breast cancer is increasing, the mortality rate is still under better control. From 2000 to 2011, the annual incidence of breast cancer in China increased at an average rate of 3.9%, while the annual increase in mortality was only 1.1%, while the mortality rate in the United States has declined by 30% since its peak in the 1990s. Effective treatment modalities have reduced the mortality rate of breast cancer, and with standardized treatment, about two-thirds of breast cancer patients can now be completely cured and one-third will develop recurrent metastases. With the promotion and popularization of breast cancer precision staging and molecular targeted therapy, breast cancer treatment is now more and more inclined to comprehensive treatment under the premise of precision and individualization, and different patients have different treatment plans. It is our goal to achieve the individualized and precise treatment model for each breast cancer patient, hoping to obtain maximum efficacy while minimizing side effects. As a new treatment model, breast cancer treatment under the guidance of precision medicine has become a major trend. Individualized treatment allows for increasingly precise treatment of different populations. Molecular genotyping has improved the prognosis of breast cancer patients through “categorization and treatment”. The advent of targeted therapy 15 years ago has meant that breast cancer treatment has become more precise and efficient, and breast cancer patients have a better chance of survival. Even for HER2-positive breast cancer, which has faster disease progression, higher malignancy, and greater susceptibility to recurrence and metastasis, 1-year standard anti-HER2 adjuvant therapy based on trastuzumab in the early stage significantly improves the chances of cure for early stage patients, with a 10-year disease-free survival rate of nearly 70% and a 10-year overall survival rate of nearly 80%; while for patients with advanced HER2-positive breast cancer, trastuzumab can For advanced HER2-positive breast cancer patients, trastuzumab can also significantly extend their survival, with about half of the patients having a survival of nearly 5 years when combined with pertuzumab. However, due to the high cost of targeted therapy, less than 20% of patients diagnosed currently receive anti-HER2 therapy, which is far from the 90% rate in Western countries. However, it is reassuring to see that the inclusion of neoadjuvant therapy in health insurance in various provinces will greatly alleviate much of the financial burden on patients and significantly improve the accessibility of targeted therapies. ”Neoadjuvant therapy” can predict “drug resistance” in advance. The inescapable problem in breast cancer treatment is “drug resistance”. The neoadjuvant treatment before surgery can screen patients for drug sensitivity or resistance. This means that the chemotherapy and targeted therapy that patients used to do after surgery will be done before surgery. Because the patient has visible tumor at this time, the change of tumor size can be monitored through treatment, and the speed and degree of tumor shrinkage can be seen, so as to determine whether the patient is sensitive or resistant to treatment. If chemotherapy or targeted therapy is put after surgery, the tumor is no longer clinically visible to the patient, and it is impossible to assess the response of the tumor to the subsequent treatment. Some molecular types respond well to neoadjuvant therapy, for example, patients with HER2-positive or triple-negative breast cancer have about 20-30% possibility to obtain pathological complete remission, and such patients generally have a very good prognosis and the chance of breast conservation is greatly increased. Neoadjuvant therapy is the current trend in early treatment of breast cancer. Doctors should not only be able to perform surgery and remove the tumor, but also know the biological information of the tumor and be able to accurately assess the prognosis of the patient. Neoadjuvant therapy is especially recommended for patients with triple negative and HER2-positive breast cancer who have indications for breast conservation.” He added that it is very important to have a regular breast checkup once a year. In the early stage of breast cancer, there are often no special conscious symptoms, but most of them are painless, single, hard, small lumps in the breast, with uneven surface, not easily movable and poorly demarcated from the surrounding tissues, and the lumps gradually increase in size, and in the later stage, the skin connected with the lumps is depressed and orange peel-like. With the development of modern medicine, there are many methods for early detection of breast cancer, such as mammogram and ultrasound examination. However, the most convenient method is self-examination of the breast, noting whether the size of the breast is symmetrical, whether there are small nodules, whether there are changes in the skin of the breast and the position of the breast, and if you find any suspicious changes, you should go to a hospital for a specialist examination. You can’t go to “two extremes” with breast disease: First: don’t overstress and overtreat. Even if you have benign nodules, don’t worry too much, there is no need for surgery to remove ordinary hyperplastic nodules; secondly, don’t “avoid treatment”. Early detection and treatment of breast cancer is of great significance to patients. The age of onset of breast cancer in Chinese women is between 45-55 years old, and he suggested that it is necessary for women to have a special breast examination in a regular hospital every year.